Collectively, our findings emphasize the need to offer molecular screening of the β globin gene to partners of carriers of hemoglobinopathies, irrespective of their hematological indices and HbA2 levels, to avoid a misdiagnosis of these “at-risk” couples who, in turn, could have affected children. This evidence concerns the gene HBA2 and hemoglobinopathy.